



Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)



Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
 Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
 E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
 CIN No. L24232CH1995PLC015553

Particulars	STANDALONE				CONSOLIDATED				(Rs. In Lakhs)
	Quarter Ended 30.06.2019	Quarter Ended 31.03.2019	Quarter Ended 30.06.2018	Year Ended 31.03.2019	Quarter Ended 30.06.2019	Quarter Ended 31.03.2019	Quarter Ended 30.06.2018	Year Ended 31.03.2019	
	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	
Income from Operations:									
Revenue from operations	18114.74	19212.00	17876.03	72442.76	18760.87	19409.73	18511.94	75660.26	
Other Income	470.91	1242.07	400.93	3746.35	470.91	1242.07	400.93	2737.88	
Total Revenue	18585.65	20454.07	18276.96	76189.12	19231.78	20651.80	18912.87	78398.14	
EXPENSES:									
a. Cost of Materials Consumed	9322.51	8759.34	11088.21	39196.76	9514.67	8904.74	11209.25	41599.75	
b. Purchase of stock in Trade	0.00	0.00	33.35	33.35	0.00	0.00	33.35	33.35	
c. (Increase) /decrease in FG,WIP & stock in trade	424.29	1870.27	(2369.82)	(1868.19)	424.29	1870.27	(2369.82)	(1868.19)	
d. Employee benefit	2256.67	2596.49	2349.32	9549.68	2294.94	2657.28	2401.62	9753.87	
e. Finance Costs	2754.23	3452.18	490.01	8332.34	2754.23	3452.18	480.01	8333.28	
f. Depreciation	2258.32	2785.67	2527.38	10404.77	2258.32	2785.67	2527.38	10404.77	
g. Other expenditure	3208.37	2453.53	3805.50	12430.30	3370.09	2579.19	4205.39	12956.32	
TOTAL EXPENSES	20224.39	21917.48	17913.95	78079.01	20616.54	22249.33	18487.19	81213.15	
Profit/(loss) before exceptional Items and Tax	(1638.74)	(1463.42)	363.01	(1889.89)	(1384.76)	(1597.53)	425.68	(2815.01)	
Exceptional Items (Income) /loss	0.00	(733.66)	(2387.76)	(8293.55)	0.00	(733.66)	(2387.76)	(8293.55)	
Profit/(loss) before Tax (After exceptional items)	(1638.74)	(729.75)	2750.77	6403.66	(1384.76)	(863.87)	2813.44	5478.55	
Tax Expenses :-									
(1) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	38.23
(2) Income Tax Adjustment of Previous Years	0.00	335.40	0.00	335.40	0.00	335.40	0.00	335.40	
(3) Deferred Tax	0.00	1699.42	0.00	1699.42	0.00	1699.42	0.00	1699.42	
Profit (+)/ Loss (-) for the period from continuing operations	(1638.74)	(2764.58)	2750.77	4368.84	(1384.76)	(2898.70)	2813.44	3405.49	
Profit (+)/ Loss (-) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
Profit (+)/ Loss (-) from discontinuing operations (after Tax)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
Net Profit / (Loss) for the period after tax &	(1638.74)	(2764.58)	2750.77	4368.84	(1384.76)	(2898.70)	2813.44	3405.49	
Other Comprehensive Income									
A) Items that will not be reclassified to P/L A/c	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
B) Items that will be reclassified into P/L A/c	0.00	(44.22)	0.00	(44.22)	0.00	(44.22)	0.00	(44.22)	
Other Comprehensive Income / Loss for the period, net of Tax	0.00	(44.22)	0.00	(44.22)	0.00	(44.22)	0.00	(44.22)	
Total Comprehensive Income for the Period	(1638.74)	(2720.36)	2750.77	4413.05	(1384.76)	(2854.48)	2813.44	3449.70	
Paid up Equity Share Capital(Face Value of Rs. 10/- per Share)	4756.92	4756.92	4527.73	4756.92	4756.92	4756.92	4527.73	4756.92	
Reserve excluding revaluation reserves									
EPS (of Rs. 10/- each) (Not annualised)									
Basic	(3.44)	(5.91)	6.08	9.34	(2.91)	(6.09)	6.21	7.28	
Diluted	(3.44)	(5.81)	6.08	7.33	(2.91)	(6.09)	6.21	5.57	

Wazir Khan





Ind-Swift LABORATORIES Limited

(A Recognised Export House)


Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294
E-mail : info@indswifflabs.com Website : www.indswifflabs.com
CIN No. L24232CH1995PLC015553



Notes: -

1. The company has achieved an EBITDA of Rs.36.03 crores on consolidated basis during the quarter as compared to consolidated EBITDA of Rs. 33.74 crores during the quarter ended 30th June,2018.
- 2 .The Company has adopted Ind AS 116 on "Leases" with effect from April 1, 2019, applied all contracts of leases existing on April 1, 2019 by using modified retrospective approach and accordingly, comparative information for the year ended March 31, 2019 has not been restated. The Company has recognised and measured the Right-of-Use (ROU) asset and the lease liability on the remaining lease period and payments discounted using the incremental borrowing rate as at the date of initial application. The effect of adoption of Ind AS 116 on the results and earnings per share for the Quarter ended June 30, 2019 is not material.
3. In terms of Regulation 32(1) of the SEBI (LODR) Regulations, the funds raised raised through NCDs and OCDs issue, have been fully utilised for the specific purpose for which the funds were raised and there is no deviation(s) or variation(s) of utilisation of funds thereon. The Company has created security on the listed NCD.
4. No adjustment has been made in respect of deferred Taxes as per Ind-AS 12 ,as the same would be provided at year end.
5. The previous period figures have been re-grouped, re-arranged and reinstated wherever necessary.
6. The Company is exclusively in the Pharmaceutical Business segment.
7. The above standalone and consolidated results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 10th Aug, 2019.
8. The above results are available on the Stock Exchange's websites, www.bseindia.com and www.nseindia.com and on the Company's website www.indswifflabs.com

for Ind-Swift Laboratories Ltd


N.R. Munjal
Chairman cum Managing Director

Place : Chandigarh
Date: 10-08-2019